PAREXEL FOR GLOBAL TRIALS
We’ve been a trusted partner in Japan for over 25 years, providing access to one of the world’s largest pharmaceutical markets. Between the vast number of medical institutes, high quality trial data, and long product life after patent expiry, Japan is the perfect place for your next trial.
Why Choose Parexel
Break into the Japanese market with a large, experienced team
As the second largest global CRO in Japan, we have 800+ clinical staff ready to advise, design, and execute your clinical trials. In the past five years alone, we’ve conducted nearly 500 clinical projects across all phases (as of July 8, 2024) in collaboration with 60 site management organizations and 4 clinical trial networks.
Tap into our deep regulatory expertise
You can put your trust in our 30+ experts in regulatory affairs, clinical, CMC, project management, and publishing. We’ve provided 20 JNDA drug submissions, 60+ PMDA consultations, 500+ CTN submissions, 30+ in-country representatives, and more since 2015 — with extensive experience supporting foreign companies looking to conduct trials by transferring regulatory obligations to Japan.
Accelerate your trials by leveraging our strategic partnerships
By partnering with Kyoto University Hospital’s Ki-CONNECT (Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy), we’re creating more opportunities for clinical trial innovation and the advancement of new medicines to market. We’ve also partnered with the Japanese Foundation for Cancer Research (JFCR) and Osaka International Cancer Institute (OICI) to expedite access to oncology clinical trials.
